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Adeno-associated virus (AAV) vectors can deliver transgenes to diverse cell types and are therefore useful for basic
research and gene therapy. Although AAV has many advantages over other viral vectors, its relatively small
packaging capacity limits its use for delivering large genes. The available transgene size is further limited by the
existence of additional elements in the expression cassette without which the gene expression level becomes
much lower. By using alternative combinations of shorter elements, we generated a series of AAV expression
cassettes and systematically evaluated their expression efficiency in neurons to maximize the transgene size
available within the AAV packaging capacity while not compromising the transgene expression. We found that the
newly developed smaller expression cassette shows comparable expression efficiency with an efficient vector
generally used for strong gene expression. This new expression cassette will allow us to package larger transgenes
without compromising expression efficiency.
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Viral vectors are efficient tools for expressing transgenes
in diverse cell types in vitro and in vivo. The type of
virus should be selected with care, because they possess
advantages and disadvantages, depending on the purpose
of the research [1]. Adeno-associated virus (AAV) is
known to be one of the most useful viral vectors for
transgene delivery because it is not pathogenic, induces
a minimal immune response, infects both dividing and
non-dividing cells, and the transgene expression persists
for a longer time in cells. The genomes of AAV vectors
infected into the host cell exist primarily in an extra-
chromosomal state, not integrating into the host genome.
They can be inserted into only a single specific integration
site in the human genome, which may be an advantage
for stable long-term expression without insertional muta-
genesis. In addition, AAV can be readily produced in* Correspondence: kaang@snu.ac.kr
†Equal contributors
1Department of Biological Sciences, College of Natural Sciences, Seoul
National University, Seoul 151-747, Korea
Full list of author information is available at the end of the article
© 2014 Choi et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.high titers and deliver transgenes with high efficiency.
Adenovirus, herpes simplex virus (HSV), retrovirus, and
lentivirus also have their advantages in transgene deliv-
ery. However, adenovirus and HSV are not suitable for
the purpose of stable expression in non-dividing cells
such as neurons, because they only allow transient ex-
pression. They also have the disadvantage of inducing
high immune responses. Retroviruses only transduce div-
iding cells, and, in common with lentivirus, have a risk of
insertional mutagenesis [1]. For these reasons, AAV vectors
are frequently used in basic researches and are attract-
ive candidates for use in gene therapy. AAV has also
been the vector of choice in recent clinical trials of neuro-
logical diseases, including Parkinson's and Alzheimer's
disease [2].
However, the use of AAV vectors is limited by their
relatively small maximal packaging capacity [3,4]. Al-
though there is a report describing specific serotypes
with much larger packaging capacity [5], other studies
[6-8] indicated that intact genomes were not, in fact,
packaged in that case [3], and further suggested a strict
size cutoff of 5.2 kb. Efforts have been made to expandd. This is an Open Access article distributed under the terms of the Creative
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and/or recombination to split the AAV expression
cassette to two viral vectors [9]. However, the expression
efficiency is still much lower than that of a single viral
vector.
Despite these efforts, an AAV expression cassette cap-
able of delivering a large transgene with high expression
level is still not available. As a strategy to expand the
available size of transgenes in AAV, we decided to
minimize the size of the expression cassette to allow
more space for transgenes. Using an AAV expression cas-
sette known to express transgenes with high efficiency as
a template, we generated a variety of shorter cassettes.
Then we systematically evaluated their expression effi-
ciency in neurons to maximize packaging capacity while
not compromising transgene expression.
Results
Experimental strategy for modifying expression cassettes
To generate a series of AAV expression cassettes, we
used a strong expression cassette which contains neuron-
specific promoter [10], transgene encoding enhanced green
fluorescent protein (EGFP), woodchuck hepatitis posttran-
scriptional regulatory element (WPRE) [11-13], and bovine
growth hormone polyadenylation signal (bGHpA) [14,15]
as an initial template. In this expression cassette called
CWB (CaMKII, WPRE, bGHpA), three elements were
fused with minimal sized DNA linker sequences (6 bp for
each junction). First, we modified the CWB cassette by
replacing WPRE with shorter elements and examined
transgene expression efficacy of the modified cassettes
(Figure 1). Next, we generated further modified cassettes
by replacing bGHpA with shorter polyadenlyation signal
sequences and examined their transgene expression effi-
ciency (Figure 2). Each AAV vector expressing EGFP
encoded by the modified expression cassettes was trans-
duced into cultured hippocampal neurons together with
control AAV expressing a red fluorescent protein, tdTo-
mato by the CWB cassette (CWB-tdTomato). Then, we
performed western blot analysis by using antibodies
against EGFP and tdTomato to quantify normalized EGFP
expression.
Transgene expression driven by AAV expression cassettes
with modified WPRE
WPRE is a 600 bp long tripartite element containing
gamma, alpha, and beta elements, in the given order
[16] and contributes to the strong expression of trans-
genes in AAV systems [11-13]. It also enhances the ex-
pression of a transgene lacking introns. In a previous
study [17], a shortened WPRE sequence (WPRE2) con-
taining a minimal gamma element and a partial alpha-
beta element was used in an AAV vector, but its transgene
expression efficiency was not quantitatively examined. Weshortened this sequence further so that it contained only
minimal gamma and alpha elements (WPRE3). Introns are
known to possess a posttranscriptional regulatory element
that efficiently induces transport of mRNA out of the nu-
cleus and enhances mRNA stability [18]. Therefore, we
inserted a chimeric intron sequence instead of WPRE to
examine whether an intron sequence, shorter than WPRE,
could increase transgene expression comparable to WPRE.
We compared the EGFP expression efficiency of expres-
sion cassettes containing WPRE (CWB), WPRE3 (CW3B),
or a short chimeric intron (CIB), together with an expres-
sion cassette lacking any of these (CB) (Figure 1). CB that
lacks WPRE from CWB exhibited reduced EGFP expres-
sion compared to CWB (28.6% of CWB), indicating that
WPRE is critical for strong expression. The chimeric intron
did not enhance the expression of EGFP. The EGFP ex-
pression level of CW3B was not statistically different com-
pared with that of the control CWB cassette (83.4%), even
though the size of WPRE had been significantly reduced
(from 600 bp WPRE to 247 bp WPRE3, approximately
41.2% of original size).
Effects of modification in the polyadenylation signal on
transgene expression
Using CW3B as a template, we next compared the trans-
gene expression efficiency of various polyadenylation
signal sequences (Figure 2A). Aside from the CWB com-
ponent bGHpA, the SV40 early/late polyadenylation
signal is also commonly used for efficient transgene
expression in mammalian cells. Because the late polya-
denylation signal sequence acts more efficiently for
transgene expression than the early polyadenylation sig-
nal sequence due to the presence of a short upstream
element preceding the mRNA cleavage site [19,20], only
the late polyadenylation signal sequence was tested in
this study. We first designed an expression cassette con-
taining the SV40 late polyadenylation signal sequence
instead of bGHpA (CW3L). A previous study using lenti-
viral vectors showed that the upstream element in the
late SV40 polyadenylation signal enhances the function
of the polyadenylation signal to a greater extent in a tan-
dem arrangement than when alone [21]. Therefore, we
tested this in our study as well, by adding an additional
upstream sequence element prior to the full late poly-
adenylation signal (CW3SL). Because a short synthetic
polyadenylation signal was successfully used in a pre-
vious study [22], we also generated AAV expression
cassettes that have a synthetic polyadenylation signal
alone (CW3A), or together with a single (CW3SA) or
tandem upstream element of the SV40 late polyadenyla-
tion signal (CW3SSA). Compared with CW3B, the ex-
pression levels of EGFP were 106.5% by CW3L, 122.7%
by CW3SL, 49.7% by CW3A, 70.3% by CW3SA, and
76.4% by CW3SSA (Figure 2B-D).
Figure 1 Comparison of expression cassettes with modification or deletion of WPRE. A. Schematic drawings of expression cassettes tested.
Each EGFP expression cassette was transduced into hippocampal neuron cultures together with tdTomato expression cassette, which contains
complete WPRE and bGHpA. (ITR, Inverted Terminal Repeat; CaMKIIp, CaMKIIα promoter; WPRE, Woodchuck hepatitis virus posttranscriptional
regulatory element, bGHpA: bovine growth hormone polyadenylation signal, INT: chimeric intron) B-C. Representative images of cell fluorescence
(B), and western blot analysis of EGFP and tdTomato expression (C). Scale bar, 200 μm. D. Summary graph of western blot analysis shows that
the expression level of EGFP driven by CW3B having WPRE3 (247 bp) is comparable (83.4%) to CWB having WPRE (600 bp). In contrast, EGFP
expression level was significantly reduced in CIB (16.6%, P < 0.001) and CB (28.6%, P < 0.001) compared to CWB. (***P < 0.001, ANOVA Bonferroni’s
post-hoc comparison).
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We plotted the normalized EGFP expression level
against the sequence size of the posttranscriptional regu-
latory elements and polyadenylation signals (excluding
ITRs, promoters, and transgenes, which are constant for all
expression cassettes; Figure 3). Although the EGFP expres-
sion level driven by the expression cassettes increased
linearly as the size of elements increased, CW3SL andCW3L showed higher levels of EGFP expression compared
to their size. In particular, CW3SL produced comparable
EGFP expression to the parental CWB (103.4%), despite the
fact that CW3SL is substantially smaller than CWB in size.
Transgene expression by CW3SL in mice brain
We next examined whether CW3SL drove transgene ex-
pression efficiently in vivo. Either CWB-EGFP (Figure 4A)
Figure 2 Comparison of transgene expression with modification of polyadenylation signal. A. Schematic drawings of EGFP expression cassettes
having modifications in polyadenylation signal. (L: SV40 late polyadenylation signal; SL: SV40 late polyadenylation signal upstream element + SV40 late
polyadenylation signal; A: synthetic polyadenylation signal, SA: SV40 late polyadenylation signal upstream element + synthetic polyadenylation signal;
SSA: double copy of SV40 late polyadenylation signal upstream element + synthetic polyadenylation signal). B-C. Representative images of fluorescence
(B) and western blot analysis (C) of EGFP and tdTomato expression. Scale bar, 200 μm. D. Summary graph shows that CW3SL containing WPRE3, an
additional SV40 late polyadenylation signal upstream element followed by SV40 late polyadenylation signal, drives highest EGFP expression level. CW3B
and CW3L drive significantly higher expression than CW3A (P < 0.01), while CW3SL drives significantly higher expression than CW3A (P < 0.001), CW3SA
(P < 0.01), and CW3SSA (P < 0.05) (*P < 0.05, **P < 0.01, ***P < 0.001, ANOVA Bonferroni’s post-hoc comparison).
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Figure 3 The plot of optimized elements’ size against transgene expression efficiency of each expression cassette. A. Common scheme
of the expression cassette generation in this study. The target element sites varied for optimization are indicated. B. The normalized EGFP
expression level by each cassette plotted against the size of each expression cassette with modification in WPRE and bGHpA sites. Note that size
reduction of about 399 bp in these two elements in CW3SL still gives similar level of transgene expression as that of CWB.
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tdTomato into the hippocampal CA1 region in mice.
The EGFP fluorescence intensity was normalized by the
tdTomato fluorescence intensity in the expressed CA1
area to measure the expression efficiency of each ex-
pression cassette. CW3SL-EGFP showed a similar level
of expression to CWB-EGFP, although it was slightly
weaker (86.2%).
CW3SL significantly increases AAV packaging limit of
transgene
We next examined the capability of the CW3SL expres-
sion cassette for packaging larger transgenes that exceed
the packaging limit of CWB. We fused the DNA en-
coding p110γ, a phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit gamma isoform, with EGFP,
which resulted in 4.03 kb long DNA. When we cloned
this fused DNA into the CWB cassette, the size of DNA
to be packaged is 5.6 kb, which exceeds the 5.2 kb pack-
aging limit for AAV. However, the DNA length of
CW3SL-p110γ-EGFP to be packaged in AAV is 5.2 kb,
which allows successful AAV production. Although
CWB-p110γ-EGFP did produce comparable amount of virus
(6.61 × 1012 GC/ml for CWB-p110γ-EGFP, 7.01 × 1012
GC/ml for CW3SL-p110γ-EGFP; GC: genome copy),
CW3SL drove expression of p110γ-EGFP five times
more compared to CWB, demonstrating that this novelexpression cassette CW3SL improves AAV packaging
capacity for larger transgenes (Figure 5A-B).
Discussion
AAV offers many advantages as a gene delivery system
over other viral vectors; however, its strict packaging
capacity limits its use for delivering large transgenes or
large cell-type specific promoters. Techniques to divide
a gene into two AAV vectors and then combining each
segment to reconstitute the full-length sequence after
transduction by trans-splicing and recombination have
been developed, but this technique is still in its infancy
showing much lower expression efficiency compared to
a non-divided single vector [9]. Other groups have also
developed shorter expression cassettes containing a func-
tional, minimal-sized polyadenylation signal [15,22]; how-
ever, we found that they yield only very low levels of
transgene expression. To fully exploit the potential of AAV
vectors, a short expression cassette capable of supporting
proper expression levels of transgenes required for basic
and clinical applications is highly required.
In this study, we systematically compared AAV expres-
sion cassettes comprising various short regulatory ele-
ments as substitutes for the WPRE and polyadenylation
signal of a prototype cassette capable of expressing high
levels of transgenes. We found that a shortened WPRE,
named WPRE3, which contains two of the three regulatory
Figure 4 Transgene expression in the mouse brains with CW3SL expression cassette. Either CWB-EGFP (A) or CW3SL-EGFP (B) was injected
together with CWB-tdTomato into the hippocampal CA1 region. The expression levels of EGFP and tdTomato were detected by confocal fluorescence
imaging. Scale bar, 200 μm.
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(83.4%) even when reduced in size from 600 bp to 247 bp.
We then altered the polyadenylation signal of the modi-
fied expression cassette (CW3B) that contains WPRE3.
Because synthetic, minimal consensus polyadenylation
signal sequence was used successfully in conjunction
with a strong promoter in a previous study [22], we
used this 49 bp segment in AAV in conjunction with
the CaMKIIα promoter (CW3A); however, the resulting
transgene expression driven by CW3A was only 40.4%
of the original expression cassette CWB. The SV40
early/late polyadenylation signal is often used for ex-
pressing the transgene in mammalian cells. It is well
known that SV40 late polyadenylation signal is more effi-
cient due to a short upstream element sequence [19,20].
This sequence is also known to increase the efficiencyof a weak polyadenylation signal and even more so
when used in tandem [21]. In the present study, we
found that the 135 bp SV40 late polyadenylation signal
(CW3L) showed similar efficiency to that of bGHpA,
which is 223 bp (CW3B). An additional upstream elem-
ent sequence (CW3SL) further improved the efficiency
and restored the reduced level of expression from
WPRE3. The upstream element also improved the effi-
ciency of the synthetic polyadenylation signal (comparing
CW3A, CW3SA, and CW3SSA). However, these expres-
sion cassettes were not as efficient in terms of size
as the ones containing the SV40 late polyadenylation signal
(CW3L and CW3SL).
The new CW3SL cassette provided 399 bp additional
cloning capacity compared with the original template
vector CWB and produced comparable expression to
Figure 5 Utilization of CW3SL expression cassette for large transgene expression. A. Western blot analysis of p110γ-EGFP fusion protein
expression by CWB-p110γ-EGFP and CW3SL-p110γ-EGFP. B. Quantification of the western blot analysis. p110γ-EGFP expression level was normalized
to that of tubulin, which was then normalized to the average expression level by CWB-p110γ-EGFP. C. The percentage of transcripts in mouse
hippocampus with coding sequence length within every 0.4 kb. Transcripts expressed in mouse hippocampus were selected based on RNA sequencing
data (analyzed based on Ensembl Genes version 67, NCBIM37). The transcripts in the range of 2.4-4 kb (striped bars) and those in the range of 3.6-4 kb
(darker and striped bar) that exceed the packaging capacity of conventional AAV expression cassettes and CWB cassette, respectively, become available
using CW3SL cassette.
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CWB and CW3SL is approximately 3.6 kb and 4 kb
respectively. Among the transcripts expressed in the
mouse hippocampus (defined by RNA sequencing),
1.82% (488 genes) have coding sequence length within
the range of 3.6 to 4 kb (Figure 5C). Furthermore, note
that CWB represents an optimized, compact expression
cassette from which sequences not required for expression
have been eliminated in our study. Conventionally used
AAV backbones which include a commonly used neuronal
expression cassette composed of 1.3 kb CaMKIIα pro-
moter (which shows comparable expression efficiency with
0.4 kb CaMKIIα promoter [10] used in CWB), WPRE, and
human growth hormone polyadenylation signal [23-25]has a capacity of 2.4 kb. Therefore, when compared with
these conventionally used AAV cassettes, the CW3SL
construct would obtain even more cloning capacity than
399 bp. 12.40% (3324 genes) of the transcripts expressed in
the mouse hippocampus have coding sequence length
within the range of 2.4 to 4 kb. Therefore, CW3SL now
makes it possible to express larger transgenes at high effi-
ciency compared with the prototype strong expression cas-
sette CWB and other conventional expression cassettes. In
some cases, CW3SL may provide an opportunity to pack-
age larger transgenes in AAV vectors that were previ-
ously impossible to package, while in other cases it may
enable fusing a reporter such as EGFP or other fluores-
cent proteins without losing expression efficiency as we
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tested in this study could also provide a variety of clon-
ing options. Other cassettes shorter than CW3SL would
allow packaging of even longer transgenes and still
would be useful in certain experimental conditions al-
though their expression level would be lower than that
of CW3SL. The new expression cassettes described here
would also be useful for designing other derivatives.
For example, the SV40 late polyadenylation signal sup-
ported the expression of transgenes as efficiently as
vectors containing bGHpA in the presence of WPRE3
(Figure 2). Thus, the SV40 late polyadenylation signal
alone may support expression at a level similar to that
of the CB expression cassette while saving 88 bp. In
addition, an SV40 late polyadenylation signal upstream
element may further enhance the efficiency of trans-
gene expression. In this study, we used the CaMKIIα
promoter to drive transgene expression in neurons, but
it would also be possible to substitute this promoter
with other ubiquitous promoters, cell-type–specific pro-
moters, or even conditional promoters for different
applications.
Conclusions
One of the most critical limitations for application of
AAV is the strict packaging capacity. To overcome this
issue we systematically developed and compared various
expression cassettes. We found that the newly devel-
oped smaller expression cassette shows comparable
transgene expression efficiency with the efficient vec-
tor generally used for strong transgene expression in
AAV system. This new expression cassette will allow us




The expression cassettes tested in this study are shown
in Figures 1 and 2. Each element was PCR amplified and
inserted into the AAV vector pAAV-Ef1a-DIO-hChR2
(H134R)-EYFP-WPRE-pA, replacing the DNA sequences
between the inverted terminal repeats (ITRs). The back-
bone plasmid and a CaMKIIα promoter (0.4 kb) were gifts
from K. Deisseroth and T. Kaneko [26], respectively.
WPRE was amplified from pLentilox3.1, and WPRE3 was
produced by using recombinant PCR, in which the min-
imal sequences of γ and α elements were fused [16].
bGHpA was amplified from pcDNA3.1. A chimeric intron
(5´-donor site from a human β-globin intron and 3´-
acceptor site from an immunoglobulin heavy chain variable
region intron) and the SV40 late polyadenylation signal
were amplified from pZac2.1. The complete plasmid se-
quences are deposited in GenBank (GenBank accession
number KJ411911-KJ411919).AAV production
AAVs (serotype 1) were purified from HEK293T cells
that were transfected with plasmids containing each ex-
pression cassette, p5E18-RXC1, pAd-ΔF6 [27] (20 ml
medium [DMEM/10% FBS] in a 150-mm culture dish).
Three days after transfection, the medium containing
AAV particles was collected and treated with Benzonase®
(50 U/ml for 30 min at 37°C). After 1,500 rpm, 10 min
centrifugation, the supernatant was loaded onto iodixa-
nol gradients (54% 4 ml, 40% 5 ml, 25% 5 ml, and 15%
6 ml). Four milliliters of the 40% layer was collected
after ultracentrifugation (69000 rpm, 70Ti rotor). The
solution was exchanged with PBS and concentrated using
an Amicon Ultra-15 centrifugal filter unit. The titer was
measured using quantitative RT-PCR.
Viral infection and western blot analysis
AAVs expressing EGFP and tdTomato were co-infected
to DIV9 cultured hippocampal neurons derived from
E18 rat embryos (5 × 108 GC/well for a 12-well plate)
and incubated at 37°C in a CO2 incubator for 9 days.
Cells were then collected after brief washing with 1×
PBS and lysed with RIPA buffer (50 mM Tris-Cl, pH 7.6,
150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% SDS,
0.5% sodium deoxycholate) containing PIC (Protease
Inhibitor Cocktail, Roche). The cell lysate was incubated
on ice for 10 min, and SDS-gel loading buffer (50 mM
Tris-Cl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1%
bromophenol blue, 10% glycerol) was added to each
sample. For electrophoresis, equal amount of proteins
were loaded onto 12% polyacrylamide gels. Separated
proteins were then transferred onto a nitrocellulose
membrane at 4°C for 15–20 h. After blocking for 1 h
with 5% skim milk in Tris-buffered saline containing
0.1% Tween-20 (TBST) at room temperature, the mem-
branes were incubated with antibodies against either
EGFP (1:5,000 NeuroMab), red fluorescent protein (RFP;
1:10,000, Rockland) or tubulin (1:100,000), at 4°C over-
night. HRP-conjugated secondary antibodies were ap-
plied for 1 h at room temperature after washing with
TBST. Enhanced chemiluminescence (Millipore) was
used to detect antigen-antibody complexes. Images were
acquired using a ChemiDoc XRS + System (Bio-Rad), and
the densities of the bands were measured using the Image
Lab program (Bio-Rad). For western blot analysis in
Figures 1 and 2, the EGFP expression level of each expres-
sion cassette was normalized with tdTomato expression
level. For western blot analysis in Figure 5, EGFP-p110γ
levels were first normalized with tubulin levels, then nor-
malized with the average of the level for CWB.
Stereotactic viral injection and imaging
All surgical procedures were conducted under sterile
conditions and approved by the Institutional Animal Care
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http://www.molecularbrain.com/content/7/1/17and Use Committee of Seoul National University. Wild-
type C57BL/6 male mice (8 weeks of age) were anes-
thetized by i.p. injection of Zoletile and arranged in
a stereotactic frame (Stoelting Co.). The hippocampal
CA1 regions (AP: −1.8 mm, ML: ± 1.5 mm, DV: −1.7 mm)
were targeted, and an equivalent amount of AAVs (EGFP:
8 × 108 GC; tdTomato: 4 × 108 GC) were delivered by
using a 10-μL syringe pump (Hamilton Co.) at 6.0 μL/h.
After an additional 10 min of diffusion, a needle was with-
drawn and the animal’s scalp was sutured with black silk.
After 3 weeks, the brain was removed and fixed in 4%
paraformaldehyde at 4°C overnight, followed by dehydra-
tion in 30% sucrose at 4°C for 2 days. Sections (50 μm)
were prepared by using a cryostat and mounted on glass
slides with Vectashield (Vector Lab). Fluorescence images
from hippocampal CA1 region were collected using a con-
focal microscope and analyzed with ImageJ program. To
measure the EGFP expression efficiency from the virus-
infected area, tdTomato-expressed CA1 pyramidal cell
body layer was selected from each image, and the fluores-
cence intensities of EGFP and tdTomato of the region were
measured. EGFP intensity was divided by tdTomato inten-
sity to normalize the virus infusion efficiency.
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